The Holden Comprehensive Cancer Center's (HCCC) planning and evaluation activities take place in a variety of settings. These will include annual visits of the External Advisory Committee and annual consultation with program-specific advisors. Other ongoing planning and evaluation activities include implementation of the 3 years strategic plan developed over the past year, and continuation of a focused planning and evaluation effort addressing how we can better develop and support clinical trials. The HCCC will continue with quarterly meetings of the HCCC Internal Advisory Committee, an annual HCCC Leadership Retreat, planning and evaluation during monthly HCCC executive committee meetings, and planning centered around specific research opportunities during the monthly HCCC forum. These are all in addition to the planning and evaluation activities taking place within each program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA086862-14
Application #
8640086
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
14
Fiscal Year
2014
Total Cost
$30,594
Indirect Cost
$28,739
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Jiang, Cheng-Fei; Shi, Zhu-Mei; Li, Dong-Mei et al. (2018) Estrogen-induced miR-196a elevation promotes tumor growth and metastasis via targeting SPRED1 in breast cancer. Mol Cancer 17:83
Moss, Jennifer L; Xiao, Qian; Matthews, Charles E (2018) Patterns of cancer-related health behaviors among middle-aged and older adults: Individual- and area-level socioeconomic disparities. Prev Med 115:31-38
Monga, Varun; Maliske, Seth M; Kaleem, Hassan et al. (2018) Discrepancy between treatment goals documentation by oncologists and their understanding among cancer patients under active treatment with chemotherapy. Eur J Cancer Care (Engl) :e12973
Swami, Umang; Lenert, Petar; Furqan, Muhammad et al. (2018) Atezolizumab after Nivolumab-Induced Inflammatory Polyarthritis: Can Anti-PD-L1 Immunotherapy Be Administered after Anti-PD-1-Related Immune Toxicities? J Thorac Oncol 13:e102-e103
Seaman, Aaron T; Dukes, Kimberly; Hoffman, Richard M et al. (2018) The complicated 'Yes': Decision-making processes and receptivity to lung cancer screening among head and neck cancer survivors. Patient Educ Couns 101:1741-1747
Shields, Anthony F; Jacobs, Paula M; Sznol, Mario et al. (2018) Immune Modulation Therapy and Imaging: Workshop Report. J Nucl Med 59:410-417
Vijapura, Charmi; Yang, Limin; Xiong, Jinhu et al. (2018) Imaging Features of Nonmalignant and Malignant Architectural Distortion Detected by Tomosynthesis. AJR Am J Roentgenol 211:1397-1404
Brooks, Nathan A; Boland, Riley S; Strigenz, Michael E et al. (2018) Nongenitourinary complications associated with robot-assisted laparoscopic and radical retropubic prostatectomy: A single institution assessment of 1,100 patients over 11 years. Urol Oncol 36:501.e9-501.e13
Sandgren, Jeremy A; Deng, Guorui; Linggonegoro, Danny W et al. (2018) Arginine vasopressin infusion is sufficient to model clinical features of preeclampsia in mice. JCI Insight 3:
Adams, Quentin; Hopfensperger, Karolyn M; Kim, Yusung et al. (2018) Effectiveness of Rotating Shield Brachytherapy for Prostate Cancer Dose Escalation and Urethral Sparing. Int J Radiat Oncol Biol Phys :

Showing the most recent 10 out of 1080 publications